Solid Biosciences
SLDB
67 hedge funds and large institutions have $39.5M invested in Solid Biosciences in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 23 reducing their positions, and 24 closing their positions.
442% more call options, than puts
Call options by funds: $65K | Put options by funds: $12K
0.39% less ownership
Funds ownership: 4.18% → 3.8% (-0.39%)
13% less funds holding
Funds holding: 77 → 67 (-10)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
52% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 23
52% less capital invested
Capital invested by funds: $83.2M → $39.5M (-$43.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.02M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$801K |
| 3 |
Millennium Management
New York
|
+$469K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$330K |
| 5 |
E
Ergoteles
New York
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.08M |
| 2 |
BlackRock
New York
|
-$2.05M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$1.49M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$625K |
| 5 |
State Street
Boston,
Massachusetts
|
-$510K |
SLDB Hedge Fund Activity: Q2 2022 in Review
67 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2022, worth a combined $39.5M — down 52% from $83.2M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of SLDB and 16 opened new positions — a net loss of 8 holders — while 23 trimmed existing stakes and 11 added.
The largest buyer was K2 Principal Fund, opening a new position worth an estimated $2.02M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.08M sold.
- 67 institutional investors held Solid Biosciences (SLDB) as of Q2 2022, down from 77 in Q1 2022.
- Funds reported $39.5M of Solid Biosciences stock for Q2 2022, down 52% quarter-over-quarter.
- 16 funds opened new Solid Biosciences positions in Q2 2022 and 24 closed out, a net change of -8 holders.
- The largest Solid Biosciences buyer in Q2 2022 was K2 Principal Fund, an estimated $2.02M added.
- The largest Solid Biosciences seller in Q2 2022 was EcoR1 Capital, an estimated $3.08M sold.
Based on aggregated 13F filings for Q2 2022.